Group 1 - The company, Shandong Huate Dain Health Co., Ltd., has completed the bankruptcy liquidation and deregistration process for its wholly-owned subsidiary, Shandong Huate Information Technology Co., Ltd. [1][2] - The bankruptcy application was filed by Huate Information on October 20, 2023, and the court accepted the application, appointing a manager for the liquidation process [2][4] - The court declared Huate Information bankrupt on December 11, 2024, and the bankruptcy proceedings were concluded on August 13, 2025 [3][4] Group 2 - The deregistration of Huate Information will not affect the company's normal production and profitability, and it aligns with the company's strategy to focus on children's health pharmaceuticals [4] - The company has made necessary accounting adjustments related to long-term equity investments and receivables associated with Huate Information [4]

Financial Performance - The company achieved a revenue of 1.17 billion CNY in the first half of 2025, representing a year-on-year growth of 1.39% [2] - Net profit attributable to shareholders reached 337 million CNY, with a growth of 1.69% year-on-year, resulting in a net profit margin of 98.6% [2] - The net cash flow from operating activities was 674 million CNY, showing a significant increase of 61.44% compared to the previous year [2] Product Development and Market Strategy - The company focused on children's pharmaceuticals, with a strong emphasis on product development and brand extension, including new registrations for oral solutions and clinical trials for aerosol products [2] - The brand "Yike Xin" maintained a strong market presence, contributing approximately 79% to total revenue, with a sales ratio of 1.6:1 between different product lines [3][4] - Online sales accounted for 25% of total revenue, with significant growth driven by marketing reforms and the establishment of a new retail division [5][4] Brand Value and Marketing Initiatives - The brand value of "Yike Xin" was assessed at 23.126 billion CNY, ranking among the "2025 China Brand 500" [2] - The company engaged in various promotional activities, including marathons and family-oriented events, to enhance brand recognition and consumer engagement [3] Governance and Shareholder Engagement - The company completed a management restructuring, adding three new senior executives from within the organization to strengthen operational management [3] - A proposed dividend of 25 CNY per 10 shares for the 2024 fiscal year was announced, with a dividend yield exceeding 7% [3][9] Future Outlook - The company anticipates continued growth in online sales and plans to expand its product offerings in the children's health sector, particularly in response to government policies supporting child health and nutrition [6][11] - The introduction of new products, including melatonin granules, is expected to fill market gaps and leverage the company's established brand influence [7][10]